Stock listing

Kiora Pharmaceuticals, Inc.

Selected listing: A40EG5 · LS · EUR · DE

Kiora Pharmaceuticals, Inc. (Lang & Schwarz: A40EG5), Health Technology. Latest release Sep 8, 2026: Kiora Pharmaceuticals Appoints Keith J. Lane as Executive…

A40EG5:LSEURDEUpdated August 31, 2026

Ticker: Lang & Schwarz: A40EG5
Asset type: Stock
Sector: Health Technology
Industry: Pharmaceuticals: Major
Exchange: Lang & Schwarz
Currency: EUR

Latest news from Kiora Pharmaceuticals, Inc.

Kiora Pharmaceuticals Appoints Keith J. Lane as Executive Vice President of Global Clinical Development and Regulatory Affairs

September 8, 2026

Kiora Pharmaceuticals Licenses South Korean Ophthalmic Development and Commercialization Rights for KIO-301 to Chong Kun Dang Pharmaceutical Corporation

August 19, 2026

Kiora Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Corporate Update

August 7, 2026

Kiora Pharmaceuticals to Participate in Piper Sandler Virtual Ophthalmology Symposium

July 1, 2026

Kiora Pharmaceuticals Reports its Ion Channel Modulator, KIO-300, Suppressed Seizure Activity in Preclinical Epilepsy Model

June 18, 2026

All Kiora Pharmaceuticals, Inc. news →

Research Kiora Pharmaceuticals, Inc.

Kiora Pharmaceuticals, Inc. company profile

View the public company page for Kiora Pharmaceuticals, Inc. on 6ix.

Kiora Pharmaceuticals, Inc. news

Read company news and market updates connected to Kiora Pharmaceuticals, Inc..

Kiora Pharmaceuticals, Inc. investor events

Find investor webinars, events, and replay context for Kiora Pharmaceuticals, Inc..